Title
A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects
A Multicentre Phase III Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects
Phase
Phase 3Lead Sponsor
Merck SeronoStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Hepatitis CIntervention/Treatment
ribavirin interferon beta-1b ...Study Participants
257The main objective of this study is to establish interferon-beta-1a as the treatment of choice for chronic Hepatitis C with better efficacy and safety profiles in monotherapy or combination therapy.
This will be a multicenter, randomized, double-blind, placebo-controlled study with a placebo to be crossed-over to a combination of interferon-beta-1a and ribavirin or no treatment during an open-label extension phase. The duration of the trial will be 48 weeks, with a double-blind period of 12 weeks.
The study will recruit 257 eligible subjects of either sex. It will be conducted by approximately 16 Investigators / investigational centers in 3 countries (China, Hong Kong and Singapore).
Interferon-beta-1a will be administered subcutaneously at a dose of 44 microgram (mcg), three times a week up to Week 24
Matching placebo will be administered subcutaneously three times a week for 12 weeks. The placebo responders will continue the study off-treatment after Week 12 up to Week 24
Placebo non-responders at Week 12 will receive ribavirin at a dose of 1000 milligram (mg) or 1200 mg orally once daily in combination with Interferon-beta-1a, administered subcutaneously at a dose of 44 mcg three times a week, from Week 16 up to Week 24
Inclusion Criteria: Age between 18 and 65 years Have an elevated serum alanine aminotransferase (ALT) between 1.5 and 10 times the upper limit of normal Had adequate bone marrow reserve and organ function Are not pregnant and are willing to use contraception, if, of childbearing potential Are willing and able to comply with the protocol and to give written informed consent Other protocol defined inclusion criteria may apply Exclusion Criteria: Clinical evidence of liver cirrhosis or a diagnosis of definite cirrhosis on liver biopsy History of liver failure, severe retinopathy, immunologically mediated disease, cancer or epilepsy with a history of inadequately controlled seizures Any cause for the liver disease other than chronic hepatitis C Evidence of chronic renal impairment, liver cancer, unstable psychiatric disorder, known or ongoing alcohol or drug abuse Positive test at screening for Hepatitis B surface antigen, immunoglobulin M Hepatitis B core antibody and human immunodeficiency virus antibody Previous systemic treatment for Hepatitis C with an interferon or ribavirin Presence of systemic disease that might interfere with subject safety, compliance or evaluation Known allergies to acetaminophen, human serum albumin or mannitol; Glucocorticosteroids or other immunosuppressive drugs taken within 28 days of starting treatment Bearing organ transplants (except cornea) Other protocol defined exclusion criteria may apply